Daina Graybosch
Stock Analyst at Leerink Partners
(0.09)
# 4,394
Out of 4,457 analysts
496
Total ratings
38.8%
Success rate
-8%
Average return
Main Sectors:
Stocks Rated by Daina Graybosch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CGEN Compugen | Maintained: Buy | $13 → $5 | $2.16 | +131.48% | 28 | May 21, 2026 | |
| RCUS Arcus Biosciences | Maintained: Buy | $49 → $47 | $31.08 | +51.22% | 25 | Apr 20, 2026 | |
| GILD Gilead Sciences | Maintained: Buy | $114 → $129 | $126.33 | +2.11% | 28 | Apr 7, 2026 | |
| BNTX BioNTech SE | Downgraded: Hold | $107 → $113 | $94.26 | +19.88% | 67 | Feb 2, 2026 | |
| MRK Merck & Co. | Maintained: Buy | $107 → $114 | $129.38 | -11.89% | 77 | Dec 15, 2025 | |
| IPSC Century Therapeutics | Downgraded: Hold | $7 → $2 | $2.41 | -17.01% | 26 | Nov 17, 2025 | |
| SMMT Summit Therapeutics | Maintained: Sell | n/a | $14.32 | - | 7 | Oct 22, 2025 | |
| NBP NovaBridge Biosciences | Initiated Coverage: Buy | $9 | $1.98 | +354.55% | 1 | Oct 6, 2025 | |
| IPHA Innate Pharma | Downgraded: Hold | $2 | $1.90 | +5.26% | 32 | Sep 18, 2025 | |
| FATE Fate Therapeutics | Maintained: Buy | $12 → $7 | $2.42 | +189.26% | 37 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $20 → $6 | $3.91 | +53.65% | 21 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 → $10 | $0.308 | +3,146.75% | 20 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $28 | $9.27 | +202.05% | 2 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $8 | $2.85 | +180.70% | 20 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7 | $4.23 | +65.48% | 2 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $5 → $0.39 | $0.0001 | n/a | 32 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $42.15 | n/a | 1 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $6 | $3.92 | n/a | 19 | Aug 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $64.23 | n/a | 1 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $1.5 | $65.39 | n/a | 26 | Sep 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $4.09 | n/a | 1 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $5 | $0.0001 | n/a | 10 | Apr 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $25 → $1.8 | $8.56 | n/a | 8 | Apr 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | CHF 35.00 | $3.18 | n/a | 1 | Apr 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | €83.43 → €87.82 | $146.40 | n/a | 3 | Aug 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $5 | $21.32 | n/a | 1 | May 22, 2019 |
Compugen
May 21, 2026
Maintained: Buy
Price Target: $13 → $5
Current: $2.16
Upside: +131.48%
Arcus Biosciences
Apr 20, 2026
Maintained: Buy
Price Target: $49 → $47
Current: $31.08
Upside: +51.22%
Gilead Sciences
Apr 7, 2026
Maintained: Buy
Price Target: $114 → $129
Current: $126.33
Upside: +2.11%
BioNTech SE
Feb 2, 2026
Downgraded: Hold
Price Target: $107 → $113
Current: $94.26
Upside: +19.88%
Merck & Co.
Dec 15, 2025
Maintained: Buy
Price Target: $107 → $114
Current: $129.38
Upside: -11.89%
Century Therapeutics
Nov 17, 2025
Downgraded: Hold
Price Target: $7 → $2
Current: $2.41
Upside: -17.01%
Summit Therapeutics
Oct 22, 2025
Maintained: Sell
Price Target: n/a
Current: $14.32
Upside: -
NovaBridge Biosciences
Oct 6, 2025
Initiated Coverage: Buy
Price Target: $9
Current: $1.98
Upside: +354.55%
Innate Pharma
Sep 18, 2025
Downgraded: Hold
Price Target: $2
Current: $1.90
Upside: +5.26%
Fate Therapeutics
Sep 4, 2025
Maintained: Buy
Price Target: $12 → $7
Current: $2.42
Upside: +189.26%
Sep 4, 2025
Maintained: Hold
Price Target: $20 → $6
Current: $3.91
Upside: +53.65%
Sep 4, 2025
Reiterated: Buy
Price Target: $12 → $10
Current: $0.308
Upside: +3,146.75%
Aug 15, 2025
Reiterated: Buy
Price Target: $28
Current: $9.27
Upside: +202.05%
Aug 13, 2025
Maintained: Buy
Price Target: $8
Current: $2.85
Upside: +180.70%
Aug 13, 2025
Reiterated: Buy
Price Target: $7
Current: $4.23
Upside: +65.48%
May 14, 2025
Downgraded: Hold
Price Target: $5 → $0.39
Current: $0.0001
Upside: n/a
Sep 17, 2024
Reiterated: Buy
Price Target: n/a
Current: $42.15
Upside: n/a
Aug 28, 2024
Maintained: Hold
Price Target: $6
Current: $3.92
Upside: n/a
Dec 11, 2023
Maintained: Buy
Price Target: n/a
Current: $64.23
Upside: n/a
Sep 15, 2023
Maintained: Hold
Price Target: $1.5
Current: $65.39
Upside: n/a
Jun 5, 2023
Maintained: Buy
Price Target: n/a
Current: $4.09
Upside: n/a
Apr 27, 2022
Maintained: Buy
Price Target: $5
Current: $0.0001
Upside: n/a
Apr 1, 2022
Downgraded: Hold
Price Target: $25 → $1.8
Current: $8.56
Upside: n/a
Apr 6, 2021
Maintained: Buy
Price Target: CHF 35.00
Current: $3.18
Upside: n/a
Aug 25, 2020
Maintained: Buy
Price Target: €83.43 → €87.82
Current: $146.40
Upside: n/a
May 22, 2019
Maintained: Hold
Price Target: $5
Current: $21.32
Upside: n/a